|
|
|
|
|
Trepanier, Lauren A
 Lauren A. Trepanier, DVM, PhD
Professor
Research Area: Drug Hypersensitivity. Drug Detoxification. Cytochrome b5. Cytochrome b5 Reductase. Arylamines, nitroso compound and hydroxylamines. Sulfonamide drug hypersensitivity.
Home Dept: Medical Sciences, School of Veterinary Medicine
Affiliated Depts: Molecular and Environmental Toxicology
Address
4254 Veterinary Medicine Building
2015 Linden
Madison, WI 53706
Phone: 608/265-9022 - Email
Research
Dr. Trepanier's research area is genetically determined differences in drug metabolism and their effects on the individual risk of drug toxicity. The major focus of her laboratory is the effect of variability in arylamine detoxification pathways (cytochrome b5 and its reductase, and antioxidant pathways), on the outcome of sulfonamide drug hypersensitivity reactions and on the risk of arylamine carcinogenesis.
Publications - Bhusari S, Padilla ML, Pinkerton ME, Drescher NJ, Trepanier LA. Combined ascorbate and glutathione deficiency leads to decreased cytochrome b (5) expression and impaired reduction of sulfamethoxazole hydroxylamine. Arch Toxicol. 2010 Mar 11. [Epub ahead of print]
- Sacco JS, Trepanier LA. Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction. Pharmacogenetics and Genomics. 20: 26-37, 2010.
- Lavergne SN, Drescher NJ, Trepanier LA. Anti-myeloperoxidase and anti-cathepsin G antibodies in sulfonamide hypersensitivity Clin Exp Allergy 38: 199-207, 2008.
- Lavergne SN, Trepanier LA. Anti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopenia Platelets 18: 595-604, 2007.
- Kurian JR, Longlais BJ, Trepanier LA. Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity. Pharmacogenetics and Genomics 17: 497-603, 2007.
- Kurian JR, Chin NA, Longlais BJ, Hayes KL, Trepanier LA. Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. Chem Res Toxicol 19: 1366-73, 2006.
- Lavergne SN, Danhof R, Volkman E, Trepanier LA. Association of drug-protein adducts and anti-drug antibodies in a clinical model of sulfonamide hypersensitivity. Clin Exp Allergy 36: 907-15, 2006.
- Lavergne SN, Kurian JR, Bajad SU, Maki JE, Yoder AE, Guzinski MV, Graziano FM, Trepanier LA. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology 222: 25-36, 2006.
- Trepanier LA, Bajad SU, Kurian JR. Evaluation of the cytochrome b5 / cytochrome b5 reductase pathway Current Protocols in Toxicology 4.16.1-4.16.17, 2005.
- Lavergne SN, Volkmann EM, Maki JE, Yoder AR, Trepanier LA. Evaluation of the clinical, immunologic, and biochemical effects of sulfamethoxazole-nitroso administration to dogs: a pilot study. Toxicology 208: 63-72, 2005.
- Kurian JR, Bajad S, Miller JL, Chin N, Trepanier LA. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 311:1171-8, 2004.
- Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 27: 129-138, 2004.
- Trepanier LA, Yoder AR, Bajad S, Beckwith MD, Bellehumeur JL, Graziano FM. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole nitroso in HIV infection. J Acquir Immunodef Syndr 36: 1041-1050, 2004.
Check PubMed for other publications by Lauren Trepanier
|
|
|
Graduate Seminar Presentations
10/20/11
Individual variability in the detoxification of environmental carcinogens
|
|
|
